Compare KLXE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | KLXE | BOLD |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.6M | 36.5M |
| IPO Year | 2018 | 2024 |
| Metric | KLXE | BOLD |
|---|---|---|
| Price | $3.73 | $1.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 310.4K | ★ 402.4K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $636,600,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.46 | $0.96 |
| 52 Week High | $3.95 | $1.72 |
| Indicator | KLXE | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 69.08 | 65.14 |
| Support Level | $1.59 | $1.08 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.29 | 0.09 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 87.64 | 57.14 |
KLX Energy Services Holdings Inc is a growth-oriented provider of diversified oilfield services to onshore oil and natural gas exploration and production (E&P) companies operating in both conventional and unconventional plays in all of the active basins throughout the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Southwest region.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.